Sign In
Buy NDAQ
$77.65
-3.96 (-4.85%)
At Close: Jun 25, 2026
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Sep 2024
WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant da
Foresight Receives Nasdaq Notification Regarding Minimum Bid Requirements
04:05pm, Friday, 06'th Sep 2024
Ness Ziona, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems, ann
Lifecore Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Sep 2024
CHASKA, Minn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization
Preparing To Bet Against Nasdaq With The PSQ ETF
12:48pm, Friday, 06'th Sep 2024
With a P/E ratio of 41 for the Nasdaq composite it is hard to build a bull case going forward, while odds of a correction being triggered are arguably rising. The PSQ inverse ETF offers investors a me
Nasdaq Down Over 400 Points; Braze Shares Tumble After Q2 Results
12:22pm, Friday, 06'th Sep 2024
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 400 points on Friday.
Nasdaq Halts BAIYU Holdings, Inc.
11:04am, Friday, 06'th Sep 2024
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted on September 5, 2024 in BAIYU Holdings, Inc. (Nasdaq: BYU) at 19:50:00 Eastern T
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Sep 2024
DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 06'th Sep 2024
PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
Nasdaq Announces New Leadership and Structure for Financial Crime Management Technology
07:00am, Friday, 06'th Sep 2024
Appoints 13-year Nasdaq Verafin Veteran, Stephanie Champion, as New Head of Nasdaq Verafin Nasdaq Chief Strategy Officer, Jeremy Skule, to Take on Expanded Role as Executive Chair of Nasdaq's Financia
Nasdaq Implements AxiomSL Revenue Recognition Change
07:00am, Friday, 06'th Sep 2024
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today announced that it has implemented a change to the accounting treatment of the revenues associated with AxiomSL on-premise
Forget the Nasdaq -- Buy This Magnificent ETF Instead
04:45am, Friday, 06'th Sep 2024
The Nasdaq Composite Index has trounced the S&P 500 during the past decade. But one ETF has beaten the Nasdaq in that time period.
Faraday Future Regains Compliance with All Nasdaq Continued Listing Criteria
10:38pm, Thursday, 05'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (Nasdaq: FFIE) (“FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company
Vine Hill Capital Investment Corp. Announces Pricing of $200 Million Initial Public Offering
07:21pm, Thursday, 05'th Sep 2024
Fort Lauderdale, Florida, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vine Hill Capital Investment Corp. (the “Company”), a special purpose acquisition company, today announced the pricing of its initial p
Nasdaq to Hold Teach-In Regarding AxiomSL Revenue Recognition Change
04:05pm, Thursday, 05'th Sep 2024
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) has scheduled a teach-in to discuss a change to the accounting treatment of the revenues associated with AxiomSL on-premises su
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 05'th Sep 2024
WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
